Abstract

Neisseria adhesin A (NadA), one of the surface adhesins of Neisseria meningitides (NM), interacts with several cell types including human brain microvascular endothelial cells (hBMECs) and play important role in the pathogenesis. Receptor binding pockets of NadA are localized on the globular head domain (A33 to K69) and the first coiled-coil domain (L121 to K158). Here, the phage display was used to develop a variable heavy chain domain (VHH) that can block receptor binding sites of recombinant NadA (rec-NadA). A phage library displaying VHH was panned against synthetic peptides (NadA-gdA33−K69 or NadA-ccL121−K158), gene encoding VHH was amplified from bound phages and re-cloned in the expression vector, and the soluble VHHs containing disulfide bonds were overexpressed in the SHuffle E. coli. From the repertoire of 96 clones, two VHHs (VHHF3–binding NadA-gdA33−K69 and VHHG9–binding NadA-ccL121−K158) were finally selected as they abrogated the interaction between rec-NadA and the cell receptor. Preincubation of NM with VHHF3 and VHHG9 significantly reduced the adhesion of NM on hBMECs in situ and hindered the traversal of NM across the in-vitro BBB model. The work presents a phage display pipeline with a single-round of panning to select receptor blocking VHHs. It also demonstrates the production of soluble and functional VHHs, which blocked the interaction between NadA and its receptor, decreased adhesion of NM on hBMECs, and reduced translocation of NM across BBB in-vitro. The selected NadA blocking VHHs could be promising molecules for therapeutic translation.

Highlights

  • Neisseria meningitidis (NM) causing invasive meningococcal disease (IMD) is predominantly noticed in infants and young adults with higher rates of fatality, while survivors exhibit long term sequelae (ECDC European centre for disease prevention and control, 2015)

  • The licensed prophylactic vaccines have reduced the prevalence of fatal IMD in the recent years (Pelton, 2016; Presa et al, 2019), meningitis caused by Neisseria meningitides (NM) remains a medical emergency and warrants standard therapy of antibiotics such as cephalosporin, vancomycin, and ceftriaxone (Hoffman and Weber, 2009)

  • The recombinant form of Neisseria adhesin A (NadA), spanning 161 amino acids from S1 to V175 was produced in E. coli M 15 strain (Qiagen, Germany) that encompasses both globular head domain (A24 to G85) and the first coiled-coil domain (L86 to A170) (Figures 1A,B)

Read more

Summary

Introduction

Neisseria meningitidis (NM) causing invasive meningococcal disease (IMD) is predominantly noticed in infants and young adults with higher rates of fatality, while survivors exhibit long term sequelae (ECDC European centre for disease prevention and control, 2015). There are 13 serogroups of NM differentiated based on biochemical composition of polysaccharide capsule, only A, B, C, W, and Y serogroups cause invasive outbreaks throughout the VHH Against NadA of Neisseria world (Harrison et al, 2009). The licensed prophylactic vaccines have reduced the prevalence of fatal IMD in the recent years (Pelton, 2016; Presa et al, 2019), meningitis caused by NM remains a medical emergency and warrants standard therapy of antibiotics such as cephalosporin, vancomycin, and ceftriaxone (Hoffman and Weber, 2009). Alternative strategies are being explored to treat such serious infectious diseases

Objectives
Methods
Results
Discussion
Conclusion
Full Text
Paper version not known

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.